Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting

FEMS Immunology and Medical Microbiology

Volumn 54, Issue 1, 2008, Pages 18-26

  Fotouhi, Fatemeh ^a   Soleimanjahi, Hoorieh ^a   Roostaee, Mohammad Hassan ^a   Behzadian, Farida ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

DNA vaccine; Herpes simplex virus type 2; Insect cells; Protein boosting; Protein expression; Subunit vaccine

Indexed keywords

DNA VACCINE; GLYCOPROTEIN D; PLASMID VECTOR; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE ISOLATION; GENETIC TRANSFECTION; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOLECULAR CLONING; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; HELA CELLS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNIZATION, SECONDARY; RECOMBINANT PROTEINS; SPODOPTERA; TRANSFECTION; VACCINES, DNA; VACCINES, SUBUNIT; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 51349113312     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2008.00438.x     Document Type: Article

References (29)

1. Anderson D, Harris R, Polayers D, Ciccarone V, Donahue R, Gerald G, Jessee J Luckow V (1995) Rapid generation of recombinant baculovirus and expression of foreign genes using the BAC-to-BAC Baculovirus expression system. FOCUS 17: 53 58.
2. Baghian A, Choujenko VN, D'auvergne O, Newman MJ, Baghian S Kousoulas KG (2002) Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunization with herpes simplex virus type-1 genes specifying glycoprotein B and D. J Med Microbiol 51: 350 357.
3. Bernstein DI Stanberry LR (1999) Herpes simplex virus vaccines. Vaccine 17: 1681 1689.
4. Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M Stanberry LR (2003) Herpes simplex virus type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 and HSV-2 disease in guinea pigs. J Infect Dis 187: 542 549.
5. Bourne N, Milligan GN, Stanberry LR, Stegall R Pyles RB (2005) Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus Type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192: 2117 2123.
6. Dalai SK, Pesnicak L, Miller GF Straus SE (2002) Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice. J Neurovirol 8: 35 44.
7. Eo SK, Gierynska M, Kamar AA Rouse BT (2001) Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 166: 5473 5479.
8. Flo J (2003) Co-immunization with plasmids coding the full length and a soluble form of glycoprotein D of HSV-2 induces protective cellular and humoral immune response in mice. Vaccine 21: 1239 1254.
9. Fotouhi F, Roostaee MH, Soleimanjahi H, Haqshenas GR Jamalidoust M (2005) Construction of an eukaryotic expression vector encoding herpes simplex virus type 2 glycoprotein D and in vitro expression of the desired protein. Arch Razi Ins 59: 1 11.
10. Jazayeri M, Soleimanjahi H, Fotouhi F, Bamdad T Jamali A (2007) Evaluation of cross immune response in DNA based vaccinated mice against HSV-1 and HSV-2. Gene Ther Mol Biol 11: 263 268.
11. Landolfi V, Zarley CD, Abramovitz AS, Figeroa N, Wu SL, Blasiak M, Ishizaka ST Mishkin EM (1993) Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge. Vaccine 11: 407 414.
12. Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL Corey L (1995) A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med 122: 889 898.
13. Lee HH, Cha SC, Jang DJ, Lee JK, Choo DW, Kim YS, Uh HS Kim SW (2002) Immunization with combined HSV-2 glycoproteins B2-D2 gene DNAs: protection against lethal intravaginal challenges in mice. Virus Genes 25: 179 188.
14. Li B, Wu HY, Qian XP, Li Y Chen WF (2003) Expression, purification and serological analysis of hepatocellular carcinoma associated antigen HCA587 in insect cells. World J Gastroenterol 9: 678 682.
15. Luckow VA, Lee SC, Barry GF Olins PO (1993) Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J Virol 67: 4566 4579.
16. McClements WL, Armestrong ME, Keys RD Liu MA (1996) Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad USA 93: 11414 11420.
17. Meseda CA, Elkins KL, Merchlinsky MJ Weir JP (2002) Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 186: 1065 1073.
18. Mester JC, Twomey TA, Tepe ET Bernstein DI (2000) Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine 18: 875 883.
19. Natuk RJ, Cooper D, Guo M et al 2006) Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 80: 4447 4457.
20. Nicola AV, Ponce de Leon M, Xu R, Hou W, Whitebeck JC, Krummenacher C, Montgomery RI, Spear PG, Eisenberg RJ Cohen GH (1998) Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM. J Virol 72: 3595 3601.
21. Ramshaw IA Ramsay AJ (2000) The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21: 163 165.
22. Sambrook J Russell DW (2001) Molecular Cloning: A Laboratory Manual, 3rd edn. Cold Spring Harbor, NY.
23. Simmons A Nash AA (1985) Role of antibody in primary and recurrent herpes simplex virus infection. J Virol 53: 944 948.
24. Sin JI, Bagarazzi M, Pachuk C Weiner DB (1999) DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responces in a murine herpes simplex virus-2 gD vaccine model. DNA Cell Biol 18: 771 779.
25. Soleimanjahi H, Roostaee MH, Rasaee MJ, Mahboudi F, Kazemnejad A, Bamdad T Zandi K (2006) The effect of DNA priming-protein boosting in enhancing the humoral immunity and protecting the mice against lethal HSV infections. FEMS Immunol Med Microbiol 46: 100 106.
26. Straus SE, Savarese B, Tigges M et al 1993) Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by a recombinant glycoprotein D vaccine. J Infect Dis 167: 1045 1052.
27. Tang L, Zhou Z, Chen Y, Luo Y, Wang L, Chen L, Huang F, Zeng X Yi X (2007) Vaccination of goats with 31 kDa and 32 kDa Schistosoma japonicum antigens by DNA priming and protein boosting. Cell Mol Immunol 4: 153 156.
28. Wachsman M, Kulka M, Smith CC Aurelian L (2001) A growth and latency compromised herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 19: 1879 1890.
29. Weiss H (2004) Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 1: 24A 35A.